Research Papers:
TriCurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3069 views | HTML 5362 views | ?
Abstract
Longzhu Piao1,2, Sumit Mukherjee3,4, Qing Chang4,5, Xiujie Xie1,2, Hong Li6, Mario R. Castellanos7, Probal Banerjee3,4, Hassan Iqbal1,2, Ryan Ivancic1,2, Xueqian Wang1,2, Theodoros N. Teknos1,2 and Quintin Pan1,2
1Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA
2Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
3Ph.D. Program in Biochemistry at the Graduate Center of the City University of New York, New York, USA
4Department of Chemistry and Center for Developmental Neuroscience, College of Staten Island, Staten Island, New York, USA
5Department of Pathology and Laboratory Medicine, Staten Island University Hospital, Northwell Health, Staten Island, New York, USA
6Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA
7Division of Research, Department of Medicine, Staten Island University Hospital, Northwell Health, Staten Island, New York, USA
Correspondence to:
Quintin Pan, email: [email protected]
Keywords: human papillomavirus, p53, head and neck cancer, curcumin, catechin
Received: December 22, 2015 Accepted: May 13, 2016 Published: July 16, 2016
ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide with about 600,000 new cases diagnosed in the last year. The incidence of human papillomavirus-positive head and neck squamous cell carcinoma (HPV-positive HNSCC) has rapidly increased over the past 30 years prompting the suggestion that an epidemic may be on the horizon. Therefore, there is a clinical need to develop alternate therapeutic strategies to manage the growing number of HPV-positive HNSCC patients. TriCurin is a composition of three food-derived polyphenols in unique stoichiometric proportions consisting of curcumin from the spice turmeric, resveratrol from red grapes, and epicatechin gallate from green tea. Cell viability, clonogenic survival, and tumorsphere formation were inhibited and significant apoptosis was induced by TriCurin in UMSCC47 and UPCI:SCC090 HPV-positive HNSCC cells. Moreover, TriCurin decreased HPV16E6 and HPV16E7 and increased p53 levels. In a pre-clinical animal model of HPV-positive HNSCC, intra-tumoral injection of TriCurin significantly inhibited tumor growth by 85.5% compared to vehicle group (P < 0.05, n = 7). Our results demonstrate that TriCurin is a potent anti-tumor agent for HPV-positive HNSCC. Further development of TriCurin as a novel anti-cancer therapeutic to manage the HPV-positive HNSCC population is warranted.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10620